Imexhs Ltd · ASX:IME
Imexhs — Shareholder Meeting (May 2023)
37 slides from Imexhs's shareholder meeting presentation, May 16, 2023
Slide 1: 2023 Annual General Meeting – Chairman and CEO Addresses
16 May 2023 ASX ANNOUNCEMENT 2023 Annual General Meeting – Chairman and CEO Addresses In accordance with ASX Listing Rule 3.13, attached are the Chairman and CEO Addresses together with the presentation slides, which will be delivered at the IMEXHS Limited Annual General Meeting commencing at 11.00
Slide 2: Chairman's Address
IMEXHS Limited Annual General Meeting 16 May 2023 Chairman’s Address As investors know, 2022 was a challenging year for markets. Midway through the year the world started to come out of its response to the Covid pandemic with countries moving at different speeds but with all central banks and govern
Slide 3: Chairman's Address: Latin America growth and RIMAB
Our strength is in Latin America, and we continue to see good growth in the key markets. Our sales of IMEXHS Cloud have mostly been through our partner program and mostly outside of Colombia. We do have direct sales and support in Mexico alongside Partners and our growth there accelerated in 2022. W
Slide 4: CEO's Address
CEO’s Address Good morning, it is a pleasure to present the CEO’s address for our 2023 Annual General Meeting. I am based in Bogota but was pleased to visit Sydney and Melbourne last month to meet IMEXHS clients and shareholders and provide an update on the company’s progress. Today we will be discu
Slide 5: CEO's Address: contract wins and path to profitability
IMEXHS has also been awarded a new expanded three-year contract with major hospital group Colsubsidio, for the outsourcing of its entire radiology services network at increased prices and additional services. It has renewed a contract with Colombia’s National Police Force, with a price increase of 1
Slide 6: CEO's Address: revenue and current trading
on-premise or remotely using IMEXHS software. Our revenue has also increased by 28% year on year, although our ARR has gone down by 21%. Turning to slide 14, current trading and update. The company recently announced a Famisanar contract with ARR of $1.1 million, which commenced operations and billi
Slide 7: CEO's Address: product releases and FY23 plan
We're also introducing a new Viewer with Walkthrough and Oblique MPR features, and Aquila 4.0, which will include several enhancements. Our new Portal version, 3.01 will have role selection, share report, mobile optimization, updated viewer, and about label. Moreover, our Enterprise Imaging & Imexhs
Slide 8: Annual General Meeting
Annual General Meeting 16 May 2023
Slide 9: Board of Directors
Board of Directors Doug Flynn Carlos Palacio Dr Doug Lingard Damian Banks Dr German Arango Non-Executive Non-Executive Non-Executive Non-Executive CEO & Managing Chairman Director Director Director Director IMEXHS LTD (ASX:IME) | AGM 16 May 2023 2
Slide 10: Registration & Voting
Registration & Voting 1. Log in or register at: 2. Click view and register 3. Record your vote. Once https://investor.automic.com.au/#/home your attendance for the you confirm it is lodged and meeting final To contact support: Call 1300 816 159 or open live chat from the Investor Portal
Slide 11: Agenda
Agenda 2023 AGM 1. Introductions 2. Chairman’s Address 3. CEO’s Address 4. Business of Meeting 5. Resolutions & Proxy Vote Results 4
Slide 12: Chairman's Address
Chairman’s Address Doug Flynn
Slide 13: CEO's Address
CEO’s Address Dr German Arango
Slide 14: One Company with two businesses aimed at democratising access to medical expertise
One Company with two businesses aimed at democratising access to medical expertise Medical Imaging Software Radiology Services Provider of innovative, cloud-based, Outsourcing of imaging facilities medical imaging software solutions and teleradiology to hospitals and medical facilities 7
Slide 15: Expanding global footprint
Expanding global footprint Software 18 countries; 449 sites 3,000+ radiologists 35 distributors in 15 countries Radiology Colombia, Spain and Mexico 35 radiology centres 150+ in-house radiologists 8
Slide 16: Business Highlights
Business Highlights • The Company has demonstrated the scalability of the business across different geographies with an attractive product and disruptive business model and now is focused in generating positive earnings and cashflow. • Focus is on sales within Latin America and those product develop
Slide 17: FY22 Operational Highlights
FY22 Operational Highlights • Successful implementation of a cost • Awarded new expanded 3-year contract reduction plan completed with major hospital group Colsubsidio, for the outsourcing of its entire radiology • Continued sales momentum for IMEXHS services network at increased prices and Cloud wi
Slide 18: Path to Profitability
Path to Profitability • Cost out project had the effect of decreasing run rate operating and software capex costs by circa $250k per month with the view to moving company to cash positive • Market and product development projects that did not have a clear pathway to profitability were halted. Commen
Slide 19: FY22 Financial Highlights
FY22 Financial Highlights Sales Revenue1 Annual Recurring Revenue (ARR) EBITDA Up 28% yoy $17.1m Down 4% yoy $19.7m vs ($3.0m) in FY21 ($0.8m) Up 34% on a constant Up 8% on a constant currency basis3 currency basis Debt Closing cash Underlying EBITDA2 Vs $2.4m at 31 $1.1m vs $4.2m at 31 $1.9m vs ($1
Slide 20: FY22 Business Unit Results
FY22 Business Unit Results • Software primarily relates to sales of $M Software Radiology Corporate Total IMEXHS Enterprise and growing IMEXHS Cloud business Revenue 6.4 10.7 - 17.1 ➢ Revenue up 28% yoy ➢ ARR up 30% Underlying 1.1 0.7 (1.9) (0.1) • Radiology includes RIMAB along with EBITDA other se
Slide 21: Current Trading & Update
Current Trading & Update • Famisanar contract with ARR of $1.1m • Despite reducing software development announced on 6 March 2023 and Capex, exciting development program commenced operations during February. through 2023 and beyond. Some of which is commercial in confidence. • Radiology services con
Slide 22: Software development
Software development Delivered in 2022 Strategy & Priorities • DICOM and Modality Worklist Gateway:v1.2 new product, • Prioritize high impact no longer hardware, now delivered as software reducing development, to increase margins, speed of installation, seamless integration with modality revenue, re
Slide 23: FY23 Outlook
FY23 Outlook Our Plan To be delivered through: ● Cost out project aimed at moving to cash ● To be cash positive positive and balance sheet sustainability ● Focused geographically for ● Focus on Latam countries – traction and 2023 cost of doing business ● Software development to ● Development project
Slide 24: Business of Meeting
ime «Hs Business of Meeting
Slide 25: Resolutions & Proxy Vote Results
Resolutions & Proxy Vote Results
Slide 26: Financial Report
Financial Report To receive the financial report of the Company and the reports of the Directors and of the Auditors for the financial year ended 31 December 2022. Q&A
Slide 27: Resolution 1: Remuneration Report
Resolution 1: Remuneration Report “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report for the financial year ended 31 December 2022 as disclosed in the Company’s Annual Report be adopted.” Proxy votes For Against Open 6,721,615 99,06
Slide 28: Resolution 2: Re-election of Director
Resolution 2: Re-election of Director “That, for the purpose of Article 6.3(c) of the Constitution, ASX Listing Rule 14.5, and for all other purposes, Mr Douglas Flynn, a Director, retires by rotation, and being eligible, is re-elected as a Director of the Company.” Proxy votes For Against Open 14,0
Slide 29: Resolution 3: Approval of Issue of Securities under the Long-term Incentive Plan
Resolution 3: Approval of Issue of Securities under the Long- term Incentive Plan “That, pursuant to and in accordance with Listing Rule 7.2 (Exception 13(b)) and for all other purposes, Shareholders approve the IMEXHS Limited Long Term Incentive Plan (the Plan), and the grant of the Incentive Secur
Slide 30: Resolution 4: Grant of Options to the Chief Executive Officer
Resolution 4: Grant of Options to the Chief Executive Officer “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 162,182 Options to the Managing Director & CEO, Dr German Arango, under the Plan on the terms and conditions set out in the Ex
Slide 31: Resolution 5: Grant of Options to Non-Executive Director Mr Damian Banks
Resolution 5: Grant of Options to Non-Executive Director Mr Damian Banks “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 39,726 Options to Non-Executive Director, Mr Damian Banks, under the Plan on the terms and conditions set out in th
Slide 32: Resolution 6: Grant of Options to Non-Executive Director Mr Douglas Flynn
Resolution 6: Grant of Options to Non-Executive Director Mr Douglas Flynn “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 79,453 Options to Non-Executive Director, Mr Douglas Flynn, under the Plan on the terms and conditions set out in
Slide 33: Resolution 7: Grant of Options to Non-Executive Director Dr Doug Lingard
Resolution 7: Grant of Options to Non-Executive Director Dr Doug Lingard “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 39,726 Options to Non-Executive Director, Dr Doug Lingard, under the Plan on the terms and conditions set out in th
Slide 34: Resolution 8: Grant of Options to Non-Executive Director Mr Carlos Palacio
Resolution 8: Grant of Options to Non-Executive Director Mr Carlos Palacio “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 39,726 Options to Non-Executive Director, Mr Carlos Palacio, under the Plan on the terms and conditions set out i
Slide 35: Resolution 9: Approval of 10% Share Placement Capacity
Resolution 9: Approval of 10% Share Placement Capacity "That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, Shareholders approve the Company having additional capacity to issue Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) (10% Sh
Slide 36: Disclaimer
Disclaimer The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and co
Slide 37: Annual General Meeting
Annual General Meeting 16 May 2023